Context Capex To Operating Cash Flow from 2010 to 2024

CNTX Stock  USD 1.36  0.03  2.16%   
Context Therapeutics Capex To Operating Cash Flow yearly trend continues to be fairly stable with very little volatility. Capex To Operating Cash Flow will likely drop to -0.05 in 2024. During the period from 2010 to 2024, Context Therapeutics Capex To Operating Cash Flow regression line of annual values had significance of  0 and arithmetic mean of (0.03). View All Fundamentals
 
Capex To Operating Cash Flow  
First Reported
2010-12-31
Previous Quarter
(0.05)
Current Value
(0.05)
Quarterly Volatility
0.00678672
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Context Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Context Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 435.1 K, Selling General Administrative of 9.1 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.6. Context financial statements analysis is a perfect complement when working with Context Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Context Therapeutics Correlation against competitors.
For more information on how to buy Context Stock please use our How to Invest in Context Therapeutics guide.

Latest Context Therapeutics' Capex To Operating Cash Flow Growth Pattern

Below is the plot of the Capex To Operating Cash Flow of Context Therapeutics over the last few years. It is Context Therapeutics' Capex To Operating Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Context Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Capex To Operating Cash Flow10 Years Trend
Slightly volatile
   Capex To Operating Cash Flow   
       Timeline  

Context Capex To Operating Cash Flow Regression Statistics

Arithmetic Mean(0.03)
Coefficient Of Variation(21.48)
Mean Deviation0.01
Median(0.03)
Standard Deviation0.01
Sample Variance0.000046
Range0.0194
R-Value(0.69)
Mean Square Error0.000026
R-Squared0.48
Significance0
Slope(0)
Total Sum of Squares0.0006

Context Capex To Operating Cash Flow History

2024 -0.0478
2023 -0.0456
2022 -0.0396

About Context Therapeutics Financial Statements

Context Therapeutics investors use historical fundamental indicators, such as Context Therapeutics' Capex To Operating Cash Flow, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Context Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Capex To Operating Cash Flow(0.05)(0.05)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Context Stock Analysis

When running Context Therapeutics' price analysis, check to measure Context Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Context Therapeutics is operating at the current time. Most of Context Therapeutics' value examination focuses on studying past and present price action to predict the probability of Context Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Context Therapeutics' price. Additionally, you may evaluate how the addition of Context Therapeutics to your portfolios can decrease your overall portfolio volatility.